Seminars in Hematology
Volume 43 , Pages S13-S17 , October 2006

Iron Metabolism and Iron Supplementation in Anemia of Cancer

  • Heinz Ludwig

      Affiliations

    • Corresponding Author InformationAddress correspondence to Heinz Ludwig, MD, Department of Medicine I, Center for Oncology and Hematology, Montleartstrasse 37, 1171 Vienna, Austria.

References 

  1. Henry DH, Dahl NV Ferrlecit Cancer Study Group. Iron and B12 parameters in anemic cancer patients on chemotherapy presenting for epoetin alpha (EPO) therapy. J Clin Oncol. 2004;22:8091;(suppl, abstr)
  2. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood. 2000;96:823–833
  3. Brugnara C. Iron deficiency and erythropoiesis: New diagnostic approaches. Clin Chem. 2003;49:1573–1578
  4. Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Moller B. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol. 2001;28:2430–2436
  5. Gasche C, Waldhoer T, Feichtenschlager T, Maie C, Mayer A, Mittermaier C, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol. 2001;96:2382–2387
  6. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int. 2003;64:572–578
  7. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694–1699
  8. NKF-DOQI clinical practice guidelines for vascular access (National Kidney Foundation-Dialysis Outcomes Quality Initiative). Am J Kidney Dis. 1997;30(suppl 3):S150–S191
  9. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083–4107
  10. NCCN 2005. http://professional.cancerconsultants.com/conference_nccn_2005.aspx?id=33902
  11. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40:2201–2216
  12. Auerbach M, Ballard H, Trout JR, Mcllwain M, Ackerman A, Bahrain H, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004;22:1301–1307
  13. Katodritou E, Speletas M, Kapetanos D, Zervas K, Pavlitou A, Georgiou E, et al. Evaluation of traditional and novel predictive markers of anemia response to recombinant human erythropoietin (rh-Epo) in patients with multiple myeloma and lymphoma: emerging role of functional iron deficiency. Blood. 2004;104:3690;(abstr)
  14. Henry DH, Dahl NV, Auerbach M, Aauerbach M, Tchekmedyian S, Laufman LR Ferrlecit Cancer Study Group. Intravenous ferric gluconate (FG) for increasing response to epoetin (EPO) in patients with anemia of cancer chemotherapy—Results of a multicenter, randomized trial. Blood. 2004;104:3696;(abstr)
  15. Auerbach M, Witt D, Toler W, Fierstein M, Lerner RG, Ballard H. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med. 1988;111:566–570
  16. Vandebroek A, Gaede B, Altintas S, Smith K, Yao B, Schupp M, et al. ASCO Poster Session. 2006;Atlanta, GA, June 2-6, (abstr 8612)
  17. Hedenus M, Birgegard G, Näsman P, Ahlberg L, Karlsson T, Lauri B, et al. Adjuvant intravenous iron therapy potentiates epoetin b treatment in anemic, non iron-depleted patients with lymphoproliferative disorders: Results of the NIFe Study. 2006;EHA Meeting, Amsterdam, the Netherlands, June 15-18, (abstr 0996)
  18. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–1023
  19. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med. 1988;319:1047–1052
  20. Aronoff GR, Bennett WM, Blumenthal S, Charytan C, Pennell JP, Reed J, et al. Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens. Kidney Int. 2004;66:1193–1198
  21. Innerhofer P, Klingler A, Klimmer C, Fries D, Nussbaumer W. Risk for postoperative infection after transfusion of white blood cell-filtered allogeneic or autologous blood components in orthopedic patients undergoing primary arthroplasty. Transfusion. 2005;45:103–110
  22. Beguin Y. Erythropoietic Agents and Iron. ESO Scientific Updates. 2005;6:Anemia in Cancer

 Supported by the Austrian Forum Against Cancer.

PII: S0037-1963(06)00159-4

doi: 10.1053/j.seminhematol.2006.08.008

Seminars in Hematology
Volume 43 , Pages S13-S17 , October 2006

Article Tools

* Image Usage & Resolution